Compare Boston Scientific Corporation (BSX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Xpeng Inc - ADR — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Xpeng Inc - ADR trades at $13.78 (market cap $12.77B). The key difference: Boston Scientific Corporation is far larger — about 5.2× Xpeng Inc - ADR's market cap, and Xpeng Inc - ADR is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | XPEV | |
|---|---|---|
Market Cap | $66.37B | $12.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $28.07 |
52-Week Low | $42.63 | $12.09 |
Enterprise Value | $75.94B | $14.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
XPeng (XPEV) trades at $12.95, down 0.61% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 deliveries of 103,295 vehicles, beating guidance, but continues to post net losses with a -3.06% margin. Revenue grew to $76.72B in 2025, though cash flow from operations was negative $2.01B in 2024. Analyst sentiment is mixed with 64.7% buy ratings.
The outlook hinges on XPeng's ability to achieve profitability amid expansion. Opportunities include new model launches and international growth, but risks persist from intense EV competition and ongoing cash burn. The stock's valuation at P/S of 1.14 may attract value investors if margins improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
